宣肺败毒方治疗新型冠状病毒肺炎普通型并截断其重症化的单臂研究

注册号:

Registration number:

ITMCTR2200005994

最近更新日期:

Date of Last Refreshed on:

2022-05-11

注册时间:

Date of Registration:

2022-05-11

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

宣肺败毒方治疗新型冠状病毒肺炎普通型并截断其重症化的单臂研究

Public title:

Single arm study of Xuanfei Baidu Recipe in treating common type of novel coronavirus pneumonia and truncating its severity

注册题目简写:

English Acronym:

研究课题的正式科学名称:

宣肺败毒方治疗新型冠状病毒肺炎普通型并截断其重症化的单臂研究

Scientific title:

Single arm study of Xuanfei Baidu Recipe in treating common type of novel coronavirus pneumonia and truncating its severity

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200059803 ; ChiMCTR2200005994

申请注册联系人:

李亚鼎

研究负责人:

周秉舵

Applicant:

Li Yading

Study leader:

Zhou Bingduo

申请注册联系人电话:

Applicant telephone:

15921966721

研究负责人电话:

Study leader's telephone:

13301659115

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qq645212426@126.com

研究负责人电子邮件:

Study leader's E-mail:

bingduozhou@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市虹口区甘河路110号

研究负责人通讯地址:

上海市虹口区甘河路110号

Applicant address:

110 Ganhe Road, Hongkou District, Shanghai, China

Study leader's address:

110 Ganhe Road, Hongkou District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海中医药大学附属岳阳中西医结合医院

Applicant's institution:

Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013/8/26 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海中医药大学附属岳阳中西医结合医院

Primary sponsor:

Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市虹口区甘河路110号

Primary sponsor's address:

110 Ganhe Road, Hongkou District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属岳阳中西医结合医院

具体地址:

虹口区甘河路110号

Institution
hospital:

Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine

Address:

110 Ganhe Road, Hongkou District

经费或物资来源:

自筹项目

Source(s) of funding:

Self raised project

研究疾病:

新型冠状病毒肺炎

研究疾病代码:

Target disease:

Novel coronavirus pneumonia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

单臂

Single arm

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

本研究基于真实世界数据,采用单臂临床试验,评价宣肺败毒方治疗普通型新型冠状病毒肺炎并截断其重症化的临床疗效和安全性。

Objectives of Study:

In this study, based on real-world data, a single-arm clinical trial was conducted to evaluate the clinical efficacy and safety of Xuanfei Baidu Recipe in the treatment of common novel coronavirus pneumonia and its severe disease.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1、符合新型冠状病毒肺炎普通型的西医诊断标准; 2、中医证型辨证属于湿毒郁肺证型; 3、年龄≥18岁且≤80岁,性别不限; 4、理解、同意参加本研究并签署知情同意书。

Inclusion criteria

1. Meet the western medicine diagnostic criteria of the common type of coronavirus pneumonia; 2. TCM syndrome differentiation belongs to dampness-toxin stagnation lung; 3. Aged ≥ 18 years old and ≤ 80 years old, male or female; 4. Understand and agree to participate in this study and sign the informed consent.

排除标准:

1、患有肺部原发疾病,如肺部肿瘤、严重肺间质纤维化、慢性阻塞性肺疾病等; 2、合并心、脑、肝、胃肠道、肾、血液及内分泌等重要系统的严重原发性疾病; 3、在过去6个月内接受过免疫抑制治疗或器官移植者; 4、严重的精神病患者; 5、备孕中及妊娠期、哺乳期妇女者; 6、对本次研究所用药物过敏者,或由于各种情况不能配合服药及完成相关记录者; 7、研究者判断不适合参加本次临床试验者。

Exclusion criteria:

1. Patients with primary lung diseases, such as lung cancer, severe pulmonary interstitial fibrosis, chronic obstructive pulmonary disease, etc.; 2. Patients with severe primary diseases of heart, brain, liver, gastrointestinal tract, kidney, blood and endocrine system; 3. Patients who have received immunosuppressive therapy or organ transplantation in the past 6 months; 4. Patients with severe mental illness; 5. Pregnant and lactating women; 6. Patients who are allergic to the drugs used in this study, or who cannot cooperate with the medication and complete the relevant records due to various conditions; 7. Patients who are not suitable for participating in this clinical trial as judged by the researchers.

研究实施时间:

Study execute time:

From 2022-05-12

To      2023-05-01

征募观察对象时间:

Recruiting time:

From 2022-05-12

To      2023-05-01

干预措施:

Interventions:

组别:

宣肺败毒方联合西药治疗

样本量:

37

Group:

Xuanfei Baidu Recipe combined with Western Medicine

Sample size:

干预措施:

宣肺败毒方联合西药治疗

干预措施代码:

01

Intervention:

Xuanfei Baidu Recipe combined with Western Medicine

Intervention code:

样本总量 Total sample size : 37

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

定点医院

单位级别:

三级甲等

Institution/hospital:

Designated hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

中医症候积分

指标类型:

次要指标

Outcome:

TCM symptom score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生化指标

指标类型:

主要指标

Outcome:

Biochemical indicators

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治愈率

指标类型:

主要指标

Outcome:

Cure rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

重症转化率

指标类型:

次要指标

Outcome:

Severe conversion rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胸部CT

指标类型:

主要指标

Outcome:

Chest CT

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院天数

指标类型:

主要指标

Outcome:

Hospital stay

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

退热时间

指标类型:

次要指标

Outcome:

Time to fever subsidence

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

核酸转阴时间

指标类型:

主要指标

Outcome:

Nucleic acid conversion time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病死率

指标类型:

次要指标

Outcome:

Case fatality rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

待研究的结果发表1年后将原始数据公布

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data will be accessible for public one year after the results of this study published.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集使用病例报告表,随后录入SPSS软件进行数据管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection is performed with case record form, and electronic data capture is performed with SPSS software.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统